STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 3 / Line 44	Abstract (METHODS)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3-4 / Line 43-64	Abstract (METHODS, CONCLUSION)
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 5-6 / Line 69-96	Introduction/paragraph 1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5-6 / Line 84-96	Introduction/paragraph 2
Methods				
Study design	4	Present key elements of study design early in the paper	Page 6/ Line 102-103	Methods/paragraph 3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6/ Line 100-117	Methods/paragraph 3
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 6/ Line 100-117	Methods/paragraph 3
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	(N/A)	This study is an prospective case-control study. we recruited all lung procedures under CT guidance performed from November 2015 to November 2021 in our hospital. then the included patients were divided to the pneumothorax group and non-pneumothorax group according to whether or not present immediate pneumothorax after CT-LNB.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 9-12/ Line 157-229	Methods/paragraph 5-7

Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 9-12/ Line 157-229	Methods/paragraph 5-7
Bias	9	Describe any efforts to address potential sources of bias	Page 6/ Line 100-117	Methods/paragraph 3 This study is an prospective case-control study. We have formulated inclusion and exclusion criteria to control bias
Study size	10	Explain how the study size was arrived at	(N/A)	This study is an prospective case-control study. we recruited all lung procedures under CT guidance performed from November 2015 to November 2021 in our hospital.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 11-12/ Line 207-229	Methods/paragraph 7

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 12-13/ Line 231-244	Methods/paragraph 8
		(b) Describe any methods used to examine subgroups and interactions	Page 12-13/ Line 231-244	Methods/paragraph 8
		(c) Explain how missing data were addressed	(N/A)	This study is an prospective case-control study. We have formulated exclusion criteria to address missing data
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	(N/A)	This study is an prospective case-control study. We did not have any sampling strategy
		(e) Describe any sensitivity analyses	Page 12-13/ Line 231-244	Methods/paragraph 8
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 14/ Line 248-256	Results/paragraph 9
		(b) Give reasons for non-participation at each stage	(N/A)	(N/A)
		(c) Consider use of a flow diagram	Page 34	Figure1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 14/ Line 248-256 Page 30	Results/paragraph 9 Table 1
		(b) Indicate number of participants with missing data for each variable of interest	(N/A)	(N/A)
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	(N/A)	(N/A)
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	(N/A)	(N/A)
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	Page 14/ Line 248-256 Page 30	Results/paragraph 9 Table 1
		Cross-sectional study—Report numbers of outcome events or summary measures	(N/A)	(N/A)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 14/ Line 248-256 Page 30	Results/paragraph 9 Table 1
		(b) Report category boundaries when continuous variables were categorized	(N/A)	(N/A)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page 14-15/Line 284-293 Page 30 Page 33	Results/ paragraph 12, Table 1 Table 5
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 13-14/ Line 259-269	Results/paragraph 10
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 15-19/ Line 296-396	Discussion/Paragraph

				13-17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 19-20/ Line 398-404	Discussion/ Paragraph 18

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 15-19/ Line 296-396	Discussion/Paragraph 13-17
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 20/ Line 406-411	Discussion/ Paragraph 19
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	(N/A)	(N/A)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

N/A Statements: N/A stands for not applicable and may be a reasonable choice depending on the type of study performed.

Article information: https://dx.doi.org/10.21037/qims-22-474.
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.